Clinical effectiveness and safety of edoxaban in obese patients — Results of the prospective Dresden NOAC Registry (NCT01588119)

Edoxaban is a direct factor Xa inhibitors approved for stroke prevention in atrial fibrillation (SPAF) and for venous thromboembolism (VTE) treatment. Edoxaban is given in a fixed dosing regimen (with recommended dose reductions for patients with renal impairment or body weight  

Source: Thrombosis Research - June 2, 2023 Category: Hematology Authors: Luise Tittl, Christina K öhler, Sandra Marten, Christiane Naue, Kristina Fache, Laura Stanneck, Thomas Schreier, Jan Beyer-Westendorf Tags: Letter to the Editors-in-Chief Source Type: research